Safety of the PDE4 inhibitor roflumilast in COPD patients with chronic bronchitis

被引：0
|
作者：
Becker, J. C.
Pettenkofer, J.
Schmid-Wirlitsch, C. [1 ]
Gooss, A. [2 ]
机构：
[1] Nycomed Deutschland GmbH, Constance, DE, Germany
[2] Nycomed Pharma AG, Dubendorf, Switzerland
来源：
SWISS MEDICAL WEEKLY | 2010年 / 140卷 / 13-14期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：13S / 13S
页数：1
相关论文
共 50 条
  • [31] Effect of Roflumilast, a Selective PDE4 Inhibitor, on Bone Phenotypes in ADO2 Mice
    Imranul Alam
    Sara L. Hardman
    Rita L. Gerard-O’Riley
    Dena Acton
    Reginald S. Parker
    Jung Min Hong
    Angela Bruzzaniti
    Michael J. Econs
    Calcified Tissue International, 2024, 114 : 419 - 429
  • [32] The efficacy of Ariflo™ (SB 287499), a second generation, oral PDE4 inhibitor, in patients with COPD
    Compten, CH
    Gubb, J
    Cedar, E
    Nieman, RB
    Amit, O
    Brambilla, C
    Ayres, J
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1999, 159 (03) : A806 - A806
  • [33] COPD patients with chronic bronchitis and higher sputum eosinophil counts show increased type-2 and PDE4 gene expression in sputum
    Singh, Dave
    Bassi, Michele
    Balzano, Deborah
    Lucci, Germano
    Emirova, Aida
    Anna Nandeuil, Marie
    Jellema, Gera
    Afolabi, Ebenezer K.
    Leaker, Brian
    Kornmann, Oliver
    Michael Beeh, Kai
    Watz, Henrik
    Govoni, Mirco
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2021, 25 (02) : 905 - 918
  • [34] Sputum and blood transcriptomics characterisation of the inhaled PDE4 inhibitor CHF6001 on top of triple therapy in patients with chronic bronchitis
    Govoni, Mirco
    Bassi, Michele
    Vezzoli, Stefano
    Lucci, Germano
    Emirova, Aida
    Nandeuil, Marie Anna
    Petruzzelli, Stefano
    Jellema, Gera L.
    Afolabi, Ebenezer K.
    Colgan, Brendan
    Leaker, Brian
    Kornmann, Oliver
    Beeh, Kai Michael
    Watz, Henrik
    Singh, Dave
    RESPIRATORY RESEARCH, 2020, 21 (01)
  • [35] Sputum and blood transcriptomics characterisation of the inhaled PDE4 inhibitor CHF6001 on top of triple therapy in patients with chronic bronchitis
    Mirco Govoni
    Michele Bassi
    Stefano Vezzoli
    Germano Lucci
    Aida Emirova
    Marie Anna Nandeuil
    Stefano Petruzzelli
    Gera L. Jellema
    Ebenezer K. Afolabi
    Brendan Colgan
    Brian Leaker
    Oliver Kornmann
    Kai Michael Beeh
    Henrik Watz
    Dave Singh
    Respiratory Research, 21
  • [36] The modulatory effects of the PDE4 inhibitors CHF6001 and roflumilast in alveolar macrophages and lung tissue from COPD patients
    Lea, Simon
    Metryka, Alexandra
    Li, Jian
    Higham, Andrew
    Bridgewood, Charles
    Villetti, Gino
    Civelli, Maurizio
    Facchinetti, Fabrizio
    Singh, Dave
    CYTOKINE, 2019, 123
  • [37] An evaluation of roflumilast and PDE4 inhibitors with a focus on the treatment of asthma
    Al-Sajee, Dhuha
    Yin, Xuanzhi
    Gauvreau, Gail M.
    EXPERT OPINION ON PHARMACOTHERAPY, 2019, 20 (05) : 609 - 620
  • [38] Roflumilast, a Phosphodiesterases-4 (PDE4) Inhibitor, Alleviates Sepsis-induced Acute Kidney Injury
    Xu, Xingkai
    Liao, Lulei
    Hu, Baisheng
    Jiang, Hao
    Tan, Meichun
    MEDICAL SCIENCE MONITOR, 2020, 26
  • [39] Ensifentrine, a dual PDE3/PDE4 inhibitor, improves FEV1 regardless of smoking status or history of chronic bronchitis
    Rheault, Tara
    Bengtsson, Thomas
    Rickard, Kathleen
    EUROPEAN RESPIRATORY JOURNAL, 2020, 56
  • [40] The Effects of PDE4 Inhibitors Roflumilast and CHF6001 on Cytokine Production from COPD BAL Lymphocytes
    Lea, S.
    Hodgson, L.
    Southworth, T.
    Facchinetti, F.
    Villetti, G.
    Civelli, M.
    Singh, D.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
12345